pharmaphorum6d
89bio shows its NASH hand, boosting FGF21 concept
The results of a phase 2b ENLIVEN trial of FGF21 analogue pegozafermin showed it was able to reduce scarring (fibrosis) in the liver of NASH patients at more than three times the rate of a placebo ...
Nonalcoholic Steatohepatitis Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight’s, “Nonalcoholic Steatohepatitis Pipeline Insight” report provides comprehensive insights about 80+ companies ...
Hosted on MSN1mon
Leerink raises 89bio stock target to $37 on NASH study optimism
The results demonstrated a statistically significant fibrosis benefit, which Smith regards as transformational for the field and supportive of ETNB's FGF21 analog, pegozafermin, in NASH.
Nature2mon
Endocrine and liver interaction: the role of endocrine pathways in NASH
This article reviews evidence that causally links hormonal disorders with hepatobiliary disease, and gives particular focus to nonalcoholic steatohepatitis (NASH). The downstream mechanisms by ...
CNN1y
89bio Inc
Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.
Business Insider1mon
89bio’s Promising Drug Developments and Stable Financial Outlook Justify Buy Rating
The company has recently completed enrollment for its Phase 3 ENTRUST study focused on pegozafermin for severe ... for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases.